AstraZeneca Strengthens Diabetes R&D With Option On Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.